The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
Recruiting in Palo Alto (17 mi)
+78 other locations
Age: 18+
Sex: Male
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Watson Pharmaceuticals
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?
A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.
Eligibility Criteria
Inclusion Criteria
Males in good general health and at least 50 years of age, who have completed SI04009 or SI04010.
Treatment Details
Interventions
- Silodosin (Alpha Blocker)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: SilodosinExperimental Treatment1 Intervention
Silodosin 8 mg per day with food
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
NCT00224133Ocala, FL
NCT00224133Greenbelt, MD
NCT00224133Las Vegas, NV
NCT00224133Dallas, TX
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Watson PharmaceuticalsLead Sponsor